All In Biotech

Drug Trial Radar · NCT07936188

Phase 2 Study of GC4006A in Healthy Adults

A Phase 2, Randomized, Double-Blind, Active-Controlled, Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Preventive Vaccine 'GC4006A' in Healthy Adults Aged 19 to 85 Years

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingRandomized with 210 participants. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

210

Planned (sponsor's estimate)

Start

Oct 26, 2026

Primary completion

Oct 2027

Study completion May 2028

Sponsor

Lead sponsor
GC Biopharma CorpIndustry
Sponsor type
Industry
First posted
Nov 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 85 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and immunogenicity of the COVID-19 preventive vaccine 'GC4006A' in healthy adults aged 19 to 85 years

Conditions

  • Covid-19 Prevention

Interventions

  • GC4006ABiological

    Intramuscular injection

  • GC4006ABiological

    Intramuscular injection

  • COMIRNATYBiological

    Intramuscular injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Differences between groups of Neutralizing Antibody ResponsesTime frame: up to 4 weeks
  2. Differences between groups of Binding Antibody ResponsesTime frame: up to 4 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Korea University Guro Hospital

    Seoul, Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.